Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of November 3, 2026, AVTX trades at $7.32 with a market cap of $384.53M and a P/E ratio of -2.34. AVTX moved +1.95% today. Year to date, AVTX is -57.03%; over the trailing twelve months it is -59.44%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is buy with an average price target of $28.83. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for AVTX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $7.32 |
| Market Cap | $384.53M |
| P/E Ratio | -2.34 |
| EPS | $-5.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.27 |
| 52-Week Low | $3.39 |
| Volume | 1.43M |
| Avg Volume | 0 |
| Revenue (TTM) | $59.00K |
| Net Income | $-78.26M |
| Gross Margin | 0.00% |
7 analysts cover AVTX: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.83.